In a press release Tuesday, Moderna said the FDA’s Center for Biologics Evaluation and Research (CBER) told the company it would not be initiating a review of its investigational mRNA vaccine.
Moderna specified that the letter did not identify any “specific safety or efficacy concerns” with its vaccine candidate.
“The FDA rejected Moderna’s application for filing because the company refused to follow very clear FDA guidance from 2024 to test its product in a clinical trial against a CDC recommended flu vaccine to compare safety and efficacy,” FDA Commissioner Marty Makary said in a statement Wednesday.
“Moderna exposed participants, age 65 and over, to increased risk of severe illness by giving them a substandard of care against the recommendation of FDA career scientists.”
Refusing to file does not mean the application has been rejected and is not a result of evaluating the drug itself.
Moderna argued in its press release that this reasoning for refusing to file is not reflected in relevant regulations and guidance. CBER Director Vinayak Prasad reportedly overruled FDA staff reviews when deciding to reject Moderna’s application. FDA officials did not respond to this when asked on Wednesday.
When asked if Moderna could resubmit the same data, a senior FDA official said it was “entirely feasible that if they come back, maybe even show some humility.”
In response to these claims by the FDA, Moderna said in a statement to The Hill:
“The FDA reviewed and cleared the trial design as adequate before the study began 18 months ago. The industry depends on clear, transparent rules that are applied consistently in order to make the long-term investments that benefit Americans.”